SOLAR-PROMOTION-GMBH
11.7.2024 15:32:31 CEST | Business Wire | Press release
The deployment of renewable sources of energy is picking up speed around the world. The impressive results of several market surveys recently presented at The smarter E Europe 2024 prove this. Photovoltaics (PV) and storage systems in particular are experiencing dynamic growth, and the trend goes towards the combination of the two technologies. The number of large-scale PV power plants is growing rapidly, as is the number of residential, commercial and industrial PV installations combined with storage systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711733322/en/
The Global Market Outlook for Solar Power 2024-2028 highlights the dynamic growth of photovoltaics. (Graphic: Business Wire)
SolarPower Europe’s Global Market Outlook for Solar Power 2024–2028 reports a global PV growth of 87 percent in 2023 compared to the previous year. 447 gigawatts (GW) of capacity were installed, which brings the total global capacity to 1.6 terawatts (TW). To put this into perspective, only 239 GW were installed in 2022. According to the study, we are likely to exceed 2 TW of total capacity in the course of this year, after the 1 TW mark was only surmounted in 2022. Achieving the global goal of tripling renewables by 2030 will require financing, digitalizing and flexibilizing energy systems. 1 TW of PV capacity could be installed each year from 2028.
Besides, more and more countries are becoming ‘gigawatt countries’: from 31 in 2023, their number is likely to go up to 37 in 2024. In total, 576 gigawatts of renewable capacity were added last year. While PV makes up by far the largest share at 78 percent, wind power accounts for 20 percent with 117 gigawatts of total capacity. Walburga Hemetsberger, CEO of SolarPower Europe, comments: “The world has truly entered its solar age. How far solar can go will be determined by equitable global access to financing, and the political will to deliver flexible energy systems fit for the renewable reality.”
European storage market is developing dynamically
According to the European Market Outlook for Energy Storage 2024–2028 (also published by SolarPower Europe), 2023 was the year in which Europe saw high electricity prices and the desire to become independent. As a consequence, battery storage capacities skyrocketed. 17.2 gigawatt hours (GWh), that is 94 percent more than last year, were added. This development was mainly driven by the residential sector, where 12 GWh of new capacity were installed. But the commercial and industrial battery sector and on-grid batteries for large-scale energy storage also showed promising developments, adding 1.6 GWh and 3.6 GWh, respectively.
Germany: Record growth of PV
Germany is one of the four leading countries when it comes to solar energy use. The German Solar Association’s (BSW-Solar) study The German PV and Battery Storage Market underlined this with impressive figures: In 2023, added PV capacity grew by 97 percent – the highest registered growth rate in Germany ever recorded. The trend of combining PV systems with battery storage also continued. In 2019, 46 percent of all residential PV systems were installed together with battery storage systems, last year, it was 77 percent. “This trend is likely to continue as supportive regulations are expected to be introduced in the near future,” states David Wedepohl, Managing Director of International Affairs at BSW-Solar. “When combined with intelligent storage systems, the benefits for the energy system go far beyond self-consumption.”
All market surveys are available for free download via the The smarter E Digital on-demand platform:
The smarter E Europe
“Accelerating Integrated Energy Solutions“ – that’s the motto of The smarter E Europe. Europe’s largest alliance of exhibitions for the energy industry puts the spotlight on cross-industry solutions for a renewable 24/7 energy supply covering electricity, heat and transport. The smarter E Europe unites four exhibitions and will take place from May 7–9, 2025 at Messe München.
For more information, please visit: www.TheSmarterE.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711733322/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom